GKOS

Glaukos Corporation (GKOS) | Rumor.io

Glaukos

GKOS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,198

Bullish sentiment (50-day avg)96%

Price to earnings ratio-48.3

Market capitalization9.4B

Earnings per share-3.27

Dividend yield (TTM)—

Revenue (annual)507.4M

Net income (annual)-187.7M

Social

What share of all stock conversation is about GKOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

May 1

Glaukos Corporation (GKOS) stock price surged +22.84% to a new high, driven by strong EPS growth of 25%.
The company's innovative Glaukos technology is making waves in the biotech sector.
Glaukos (GKOS) 2026 stock analysis shows robust growth and significant revenue increases, but also challenges with negative net income and profitability ratios.

Generated by AI

Sentiment

Of the messages about GKOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	85.63% -3.11
Bearish	—	—	40% new	14.37% +3.11

Bullish· Aug 30

Wells Fargo raised its price target for $GKOS to $74, reiterating an Outperform rating.
JP Morgan upgraded $GKOS to Overweight with a target price of $75, citing strong potential for the company.
BMO Capital raised its price target for $GKOS to $62, and ValuEngine upgraded the stock to a Strong-Buy rating with a 6.50% expected return.

Bearish· Jul 20

Wells Fargo downgraded Glaukos to sell due to reimbursement cuts for its iStent product.
Wells Fargo analyst Lawrence Biegelsen set a price target of $41 for Glaukos, down from $100.
Glaukos' stock price may be overvalued, with some analysts suggesting it could be worth as little as $20 per share.

Generated by AI

Topics

Of the messages about GKOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	93.55%	28.11%
Announcements	—	—	6.45%	16.22%
Analysts	—	—	0%	24.9%
Earnings	—	—	0%	6.11%
Macro	—	—	0%	24.62%
Controversies	—	—	0%	0.05%

Earnings· Aug 2

Glaukos Corporation (GKOS) missed earnings per share (EPS) estimates by $0.01.
The company beat revenue estimates, reporting $43.16M in revenue for the quarter.
Glaukos raised its 2018 revenue guidance.

Analysts· Jul 20

Wells Fargo downgraded Glaukos Corporation to Underweight from Equal-Weight with a $41 price target.
The downgrade was due to concerns over reimbursement cuts for iStent, a product of Glaukos.
Lawrence Biegelsen, Wells Fargo analyst, announced the downgrade.

Announcements· Dec 14

Glaukos Corporation ($GKOS) received FDA approval for its New Drug Application (NDA) for iDose TR, a prostaglandin analog for reducing intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The approval was based on robust Phase 3 studies, including a randomized trial of 1,150 subjects across 89 sites, and is expected to lead to increased sales estimates and a potential price target of $100+ in the next year.
Glaukos reaffirmed its FY23 revenue guidance and expects FY24 revenues to be above consensus, driven by the approval of iDose TR and its potential to revolutionize glaucoma treatment.

Generated by AI

Community

Of the messages about GKOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	36.99%	31.97%
Newcomers	0%	0%	63.01%	68.03%

Regulars· Dec 14

The FDA has approved Glaukos' iDose, a development that has been in the works for over 5 years, and this approval could lead to higher forward sales estimates over time.
Glaukos has reaffirmed its FY23 revenue guidance and expects FY24 revenue to exceed consensus estimates.
The company's stock saw significant trading volume, closing up 25.36% on the day with 520% above average volume.

Newcomers· Apr 30

Glaukos Corporation has reported record sales and raised its full-year guidance due to strong performance across its product lines.
Glaukos shares have jumped 19% to a 52-week high after beating earnings estimates and raising full-year guidance.
Glaukos Q1 revenue has risen 41% to $150.6M, exceeding estimates and raising full-year guidance to $620M-$635M.

Generated by AI

News

Glaukos options activity points to bullish call spread targeting $180

1d agoInvesting.com

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.

5d agoYahoo Finance

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basis producing an average annual return of 14.97%. Currently, Glaukos has a market capitalization of $9.57 billion.

6d agoBenzinga

Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus

ALISO VIEJO, Calif., September 23, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening

7d agoYahoo Finance

Glaukos (GKOS), Why Is It Back In The Spotlight?

Glaukos (GKOS) slipped about 1% at the last close to $159.86, extending a month-long pullback of roughly 14%, even as the ophthalmic specialist posts annual revenue of $612.8 million. Glaukos shares have cooled off in the short term, with a 7 day share price return down 6.9% and a 30 day share price return down 13.5%. The broader trend is still strong, as the year to date share price return sits at 44.4% and the 1 year total shareholder return is 88.8%, which may indicate that recent weakness...

7d agoYahoo Finance

Glaukos chief development officer Tomas Navratil sells $243k in shares

11d agoInvesting.com

Also Discussed

Investors talking about GKOS also mention

#	Name	Attention
1	NVRO - Nevro Corp.	——
2	HealthEquity, Inc.HQY	0%new
3	Ollie's Bargain Outlet Holdings Inc.OLLI	0%0
4	Travere Therapeutics Inc.TVTX	0%0
5	Exelixis Inc.EXEL	0%-0.03
6	Iridex Corp.IRIX	0%0
7	ICU Medical, Inc.ICUI	0%0
8	MYR Group Inc.MYRG	0%new
9	EGRX - Eagle Pharmaceuticals, Inc.	——
10	HSKA - Heska Corporation	——

Glaukos Corporation

Healthcare
Medical Devices

Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.

Website

Location

One Glaukos Way

Aliso Viejo, CA, 92656

United States

Social

What share of all stock conversation is about GKOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

May 1

Glaukos Corporation (GKOS) stock price surged +22.84% to a new high, driven by strong EPS growth of 25%.
The company's innovative Glaukos technology is making waves in the biotech sector.
Glaukos (GKOS) 2026 stock analysis shows robust growth and significant revenue increases, but also challenges with negative net income and profitability ratios.

Generated by AI

Sentiment

Of the messages about GKOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	85.63% -3.11
Bearish	—	—	40% new	14.37% +3.11

Bullish· Aug 30

Wells Fargo raised its price target for $GKOS to $74, reiterating an Outperform rating.
JP Morgan upgraded $GKOS to Overweight with a target price of $75, citing strong potential for the company.
BMO Capital raised its price target for $GKOS to $62, and ValuEngine upgraded the stock to a Strong-Buy rating with a 6.50% expected return.

Bearish· Jul 20

Wells Fargo downgraded Glaukos to sell due to reimbursement cuts for its iStent product.
Wells Fargo analyst Lawrence Biegelsen set a price target of $41 for Glaukos, down from $100.
Glaukos' stock price may be overvalued, with some analysts suggesting it could be worth as little as $20 per share.

Generated by AI

Topics

Of the messages about GKOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	93.55%	28.11%
Announcements	—	—	6.45%	16.22%
Analysts	—	—	0%	24.9%
Earnings	—	—	0%	6.11%
Macro	—	—	0%	24.62%
Controversies	—	—	0%	0.05%

Earnings· Aug 2

Glaukos Corporation (GKOS) missed earnings per share (EPS) estimates by $0.01.
The company beat revenue estimates, reporting $43.16M in revenue for the quarter.
Glaukos raised its 2018 revenue guidance.

Analysts· Jul 20

Wells Fargo downgraded Glaukos Corporation to Underweight from Equal-Weight with a $41 price target.
The downgrade was due to concerns over reimbursement cuts for iStent, a product of Glaukos.
Lawrence Biegelsen, Wells Fargo analyst, announced the downgrade.

Announcements· Dec 14

Glaukos Corporation ($GKOS) received FDA approval for its New Drug Application (NDA) for iDose TR, a prostaglandin analog for reducing intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The approval was based on robust Phase 3 studies, including a randomized trial of 1,150 subjects across 89 sites, and is expected to lead to increased sales estimates and a potential price target of $100+ in the next year.
Glaukos reaffirmed its FY23 revenue guidance and expects FY24 revenues to be above consensus, driven by the approval of iDose TR and its potential to revolutionize glaucoma treatment.

Generated by AI

Community

Of the messages about GKOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	36.99%	31.97%
Newcomers	0%	0%	63.01%	68.03%

Regulars· Dec 14

The FDA has approved Glaukos' iDose, a development that has been in the works for over 5 years, and this approval could lead to higher forward sales estimates over time.
Glaukos has reaffirmed its FY23 revenue guidance and expects FY24 revenue to exceed consensus estimates.
The company's stock saw significant trading volume, closing up 25.36% on the day with 520% above average volume.

Newcomers· Apr 30

Glaukos Corporation has reported record sales and raised its full-year guidance due to strong performance across its product lines.
Glaukos shares have jumped 19% to a 52-week high after beating earnings estimates and raising full-year guidance.
Glaukos Q1 revenue has risen 41% to $150.6M, exceeding estimates and raising full-year guidance to $620M-$635M.

Generated by AI

Glaukos

Social

May 1

Bullish· Aug 30

Bearish· Jul 20

Earnings· Aug 2

Analysts· Jul 20

Announcements· Dec 14

Regulars· Dec 14

Newcomers· Apr 30

Glaukos options activity points to bullish call spread targeting $180

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Glaukos (NYSE:GKOS)

Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus

Glaukos (GKOS), Why Is It Back In The Spotlight?

Glaukos chief development officer Tomas Navratil sells $243k in shares

Also Discussed

Glaukos Corporation

Company Information

Location

Glaukos options activity points to bullish call spread targeting $180

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Glaukos (NYSE:GKOS)

Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus

Glaukos (GKOS), Why Is It Back In The Spotlight?

Glaukos chief development officer Tomas Navratil sells $243k in shares

Also Discussed

Social

May 1

Bullish· Aug 30

Bearish· Jul 20

Earnings· Aug 2

Analysts· Jul 20

Announcements· Dec 14

Regulars· Dec 14

Newcomers· Apr 30